Skip to main content

Epigenetics to study diseases such cancer, leukemia and multiple sclerosis

16 May 11


Press and Communications Officer
Tel.+34 93 40 37255

Biocat echoed the final meeting of the Consolider Epigenetics project, held on 12 and 13 May in Barcelona. Over the past 5 years that it has been running, this project has brought together the top European research groups in the field, including the IRB Barcelona Chromatin Structure and Function lab, led by Ferran Azorín. The project has come to an impressive end, with important findings in multiple sclerosis and cancer epigenetics and more than 150 scientific papers published in leading journals, like Cell Stem Cell, Nature Structural and Cancer Research.

About IRB Barcelona

Created in 2005 by the Generalitat de Catalunya (Government of Catalonia) and University of Barcelona, IRB Barcelona is a Severo Ochoa Centre of Excellence, a seal that was awarded in 2011. The institute is devoted to conducting research of excellence in biomedicine and to transferring results to clinical practice, thus improving people’s quality of life, while simultaneously promoting the training of outstanding researchers, technology transfer, and public communication of science. Its 27 laboratories and eight core facilities address basic questions in biology and are orientated to diseases such as cancer, metastasis, Alzheimer’s, diabetes, and rare conditions. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. It is located in the Barcelona Science Park. IRB Barcelona is a CERCA center, and a member of the Barcelona Institute of Science and Technology (BIST).